CAS: 128517-07-7; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-Diisopropyl-2-Oxa-12,13-Dithia-5,8,20,23-Tetraazabicyclo[8.7.6]Tricos-16-Ene-3,6,9,19,22-Pentaone

该化合物是一种复杂的有机化合物,其独特的双环结构包含多种功能组,包括氧和丁基.(S)和(Z)名称显示的立体化学化学学表明原子的具体空间安排,可显著地影响化合物的再活性和相互作用.多种烷基化合物的存在,如乙基乙烯和丙基-2-基,有助于形成其盐分,而双环框架则可能给分子带来僵硬性.这种化合物可能表现出有趣的化学特性,包括潜在的生物活动,因为其结构复杂.其应用将跨越不同的领域,但其特性将进一步取决于其研究,包括药物和科学.

结构式图片

欧盟法规

C&L通报

上下游产品

(3S,9S,12R,16S)-6-eth-(Z)-ylidene-3,12-diisopropyl-16-((E)-4-tritylsulfanyl-but-1-enyl)-9-tritylsulfanylmethyl-1-oxa-4,7,10,13-tetraazacyclohexadecane-2,5,8,11,14-pentaone L-Valine methyl ester (2E)-5-[(triphenylmethyl)thio]-2-pentenal (E)-5-(tritylthio)-2-penten-1-ol

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-12383499-B2
    优先权日:2018-01-01
    标题:Scale up synthesis of silicasome nanocarriers
    发明人:NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
    权利人:UNIV CALIFORNIA
    摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

    专利号:WO-2016084100-A3
    优先权日:2014-11-26
    标 题:Novel and efficient method for large scale synthesis of romidepsin
    发明人:ALAPARTHI LAKSHMI PRASAD; VASANTHAKUMAR GANGA RAMU; CHOWDARY TALLURI BHUSHAIAH; MANTRI ANAND VIJAYKUMAR; KULKARNI GAURAV
    权利人:ALAPARTHI LAKSHMI PRASAD
    摘要:The present invention relates to intermediate compounds which are used as key intermediates in the synthesis of Romidepsin and process of preparation of these intermediates. The present invention also provides processes for synthesis of Romidepsin in high purity and good yields from said intermediate compounds.

    专利号:US-2015344872-A1
    优先权日:2014-06-02
    标题 :Methods of synthesis of oligonucleotide tagged combinatorial libraries and uses thereof
    发明人:HARBURY PEHR; PAIDHUNGAT MADAN; PATTEN PHILLIP; WATTS RICHARD EDWARD
    权利人:DICE MOLECULES SV LLC
    摘要:Provided herein are methods of synthesis of a compound which includes a functional moiety operatively linked to a tagging oligonucleotide, libraries thereof and methods of using the compound and libraries thereof to identify compounds which bind to a target.

    专利号:EP-3480195-A1
    优先权日:2017-11-07
    标 题:Method for the synthesis of cyclic depsipeptides
    权利人:BAYER ANIMAL HEALTH GMBH; THE KITASATO INST
    摘要:The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, involving specific carboxylic acid group protecting tags: nTAG is preferably: nwherein m is ‰¥ 15 to ‰¤ 25, p is ‰¥ 8 to ‰¤ 18 and q is ‰¥ 15 to ‰¤ 25.

    专利号:US-12122759-B2
    优先权日:2017-11-07
    标 题:Method for the synthesis of cyclic depsipeptides
    发明人:HEIMBACH DIRK; OMURA SATOSHI; SUNAZUKA TOSHIAKI; HIROSE TOMOYASU; NOGUCHI YOSHIHIKO; Köbberling Johannes; WU ZHIJIE; FU SHUIBIAO; WU WEI; QIU JINFENG; HE LIU; WEI XUDONG
    权利人:ELANCO ANIMAL HEALTH GMBH; THE KITASATO INST
    摘要:The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.

    专利号:US-12391691-B2
    优先权日:2018-11-16
    标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
    发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
    权利人:AMGEN INC
    摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as
    台州市科瑞生物技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.pharm-intermediates.com
    企业联系电话:0576-88813233👤
    📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
    联系人:金崇光
    电话:0576-88813233
    手机:13396860566
    传真:0576-88813233
    邮箱:sales@pharm-intermediates.com
    通信地址: 台州市开发大道东段288号
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:台州市开发大道东段288号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Saijo K, Imamura J, Narita K, Oda A, Shimodaira H, Katoh T, Ishioka C. Biochemical, biological, and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors. Cancer Sci. 2014 Dec 10. doi: 10.1111/cas.12585. [Epub ahead of print] doi: 10.1186/2050-7771-2-16. eCollection 2014.
    3: Oda A, Saijo K, Ishioka C, Narita K, Katoh T, Watanabe Y, Fukuyoshi S, Takahashi O. Predicting the structures of complexes between phosphoinositide 3-kinase (PI3K) and romidepsin-related compounds for the drug design of PI3K/histone deacetylase dual inhibitors using computational docking and the ligand-based drug design approach. J Mol Graph Model. 2014 Nov;54:46-53. doi: 10.1016/j.jmgm.2014.08.007. Epub 2014 Sep 8. doi: 10.1155/2014/404078. Epub 2014 Jul 7.
    6: Satwani P, Bavishi S, Saha A, Zhao F, Ayello J, van de Ven C, Chu Y, Cairo MS. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. Cytotherapy. 2014 May 20. pii: S1465-3249(14)00548-9. doi: 10.1016/j.jcyt.2014.03.008. [Epub ahead of print] doi: 10.1371/journal.ppat.1004071. eCollection 2014 Apr.

    合成参考文献


    摘要:Journal of Antibiotics., 47(301), 1994 []
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知